Injective Co-Founder Predicts U.S. INJ ETF Launch Before 2027
Injective Co-Founder Eric Chen expects the launch of U.S. INJ ETFs before 2027. Chen made this statement at Korea Blockchain Week 2026, saying the process is moving faster than anticipated.
The two pending products are the 21Shares Injective ETF and Canary Staked INJ ETF. Both issuers filed amended S-1 statements in September, indicating active application processes.
Chen's ETF comments come alongside a broader institutional licensing strategy. Injective Institutional Services became an SEC-registered transfer agent in August, enabling the affiliated entity to maintain securities ownership records and process transfers.
Injective is also expanding institutional infrastructure through its Meridian upgrade and MiCA work. However, ETF approvals still depend on regulators and issuers.